Bank of America Reiterates Buy Rating on Optimer
According to Bank of America, Optimer Pharmaceuticals (NASDAQ: OPTR) Buy rating is reiterated.
Bank of America said that Optimer recorded $13.3mn in end market sales for its antibiotic Dificid in 4Q11, a healthy uptick from $6.9mn in 3Q11. “We expect meaningful royalty payments to Cubist in the next 2 years, as we expect the co-marketing alliance to successfully exceed sales targets.”
Optimer Pharmaceuticals closed yesterday at $12.13.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.